他克莫司群体药动学在儿童肝移植中的研究进展

Advances of population pharmacokinetics of tacrolimus in pediatric liver transplantation recipients

他克莫司治疗窗窄,药动学个体差异大,临床难以建立儿童受者的个体化治疗方案。群体药动学(PPK)在个体化给药研究方面有巨大优势。为了实现他克莫司在儿童肝移植受者中的个体化治疗,国内外学者致力于儿童肝移植受者的PPK研究,但各研究的结果存在差异。本文通过检索PubMed、Web of Science及Scopus数据库中的相关文献,着重分析了既往他克莫司PPK在儿童肝移植受者中的研究,总结影响他克莫司PPK参数的主要因素,期望应用PPK方法为构建儿童肝移植受者的个体化治疗方案奠定基础。

Tacrolimus has a narrow therapeutic window and great individual difference in pharmacokinetics, which makes it difficult to establish individualized treatment regimes for pediatric recipients. Population pharmacokinetics(PPK) has shown great advantages in individualized administration studies. In order to realize the individualized treatment of tacrolimus in pediatric liver transplant recipients, scholars were committed to PPK research in these patients, but differences were indicated in the results of each study.This relevant literature from the PubMed, Web of Science, and Scopus databases were searched, with a focus on the analysis of previous tacrolimus PPK in pediatric liver transplant recipients, and the main factors affecting tacrolimus PPK parameters were summarized. It is expected to lay the foundation for individualized therapy of pediatric liver transplant recipients by PPK method.